These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 2220538)

  • 1. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
    Kus T; Costi P; Dubuc M; Shenasa M
    Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of isoproterenol on sustained ventricular tachycardia before and during procainamide and quinidine antiarrhythmic drug therapy.
    Markel ML; Miles WM; Luck JC; Klein LS; Prystowsky EN
    Circulation; 1993 Mar; 87(3):783-92. PubMed ID: 8443899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of procainamide on ventricular tachycardia: relation to prolongation of refractoriness and slowing of conduction.
    Furukawa T; Rozanski JJ; Moroe K; Gosselin AJ; Lister JW
    Am Heart J; 1989 Oct; 118(4):702-8. PubMed ID: 2801477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
    Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
    Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative electrophysiologic findings between responders and nonresponders to class III antiarrhythmic drugs among patients with ventricular tachyarrhythmia.
    Naitoh N; Washizuka T; Takahashi K; Miyajima T; Aizawa Y
    Jpn Heart J; 1998 May; 39(3):307-19. PubMed ID: 9711182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle.
    Naitoh N; Furushima H; Ohira K; Taneda K; Aizawa Y
    Jpn Heart J; 1998 Mar; 39(2):153-61. PubMed ID: 9687824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
    Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
    Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans.
    Kidwell GA; Greenspon AJ; Greenberg RM; Volosin KJ
    Circulation; 1993 Jan; 87(1):118-25. PubMed ID: 8418998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procainamide-induced changes in reentrant ventricular tachycardia with special reference to the tachycardia-interrupting critical paced cycle length during transient entrainment with rapid pacing.
    Aizawa Y; Naitoh N; Washizuka T; Kitazawa H; Takahashi K; Kodama I; Shibata A
    Jpn Heart J; 1994 Sep; 35(5):611-23. PubMed ID: 7830326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
    Dorian P; Newman D; Berman N; Hardy J; Mitchell J
    J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
    Lee SD; Newman D; Ham M; Dorian P
    J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiologic and clinical factors influencing response to class IA antiarrhythmic agents in patients with inducible sustained monomorphic ventricular tachycardia.
    Gold RL; Haffajee CI; Alpert JS
    Am Heart J; 1986 Jul; 112(1):9-13. PubMed ID: 3728294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Na+ channel blockers vs class III antiarrhythmic drugs in treating sustained ventricular tachycardia: reversing and preventing as different electrophysiological mechanisms.
    Masotti CS; Pierangeli A
    Panminerva Med; 1999 Dec; 41(4):295-306. PubMed ID: 10705709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of antiarrhythmic efficacy of class I and III agents in patients with ventricular tachycardia by signal-averaged ECG analysis.
    Kulakowski P; Bashir Y; Heald S; Paul V; Anderson MH; Gibson S; Malik M; Camm AJ
    Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 2):2116-21. PubMed ID: 1279610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of nadolol alone or in combination with a type IA antiarrhythmic drug in sustained ventricular tachycardia: a prospective study.
    Munsif AN; Saksena S
    Pacing Clin Electrophysiol; 1989 Nov; 12(11):1816-26. PubMed ID: 2478982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of rate on prolongation of ventricular refractoriness by quinidine in humans.
    Rosenheck S; Sousa J; Calkins H; Kadish AH; Morady F
    Pacing Clin Electrophysiol; 1990 Nov; 13(11 Pt 1):1379-84. PubMed ID: 1701891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of the electrophysiology laboratory for evaluation of proarrhythmic drug response in coronary artery disease.
    Buxton AE; Rosenthal ME; Marchlinski FE; Miller JM; Flores B; Josephson ME
    Am J Cardiol; 1991 Apr; 67(9):835-42. PubMed ID: 1707220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans.
    Sager PT; Follmer C; Uppal P; Pruitt C; Godfrey R
    Circulation; 1994 Oct; 90(4):1811-9. PubMed ID: 7923666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of class I and III antiarrhythmic drugs on ventricular tachycardia-interrupting critical paced cycle length with rapid pacing.
    Naitoh N; Washizuka T; Takahashi K; Aizawa Y
    Jpn Circ J; 1998 Apr; 62(4):267-73. PubMed ID: 9583460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle.
    Naitoh N; Taneda K; Tagawa M; Furushima H; Yamaura M; Aizawa Y
    Jpn Heart J; 1998 May; 39(3):297-305. PubMed ID: 9711181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.